Table 1.
Demographics and clinical characteristics at the time of initiating TNFi therapy
| Characteristic | Single therapy N = 262 | Interrupted therapy N = 142 | Switched therapy N = 159 |
|---|---|---|---|
| Age, mean years (95% CI) | 63.1 (61.9–64.3) | 57.8 (55.7–59.9) | 59.0 (57.5–60.5) |
| Sex, % men (95% CI) | 81 (76–85) | 92 (87–96) | 91 (86–95) |
| Race, % (95% CI) | |||
| White/Caucasian | 79 (73–83) | 65 (56–73) | 77 (70–83) |
| Black/African American | 15 (11–20) | 26 (19–34) | 16 (10–22) |
| Hispanic | 3 (1.3–6.0) | 4 (1.6–9.0) | 5 (2.1–9.7) |
| American Indian/Pacific Islander | 1 (0.2–3.3) | 2 (0.4–6.0) | 1 (0.15–4.5) |
| Asian | 0 | 1 (0.2–5.0) | 0 |
| Other/unknown | 2 (0.6–4.4) | 1 (0.2–5.0) | 1 (0.15–4.5) |
| Disease duration, mean years (95% CI) | 10.6 (9.3–11.9) | 10.9 (9.1–12.7) | 9.8 (8.3–11.3) |
| RF positive, % (95% CI) | 79 (74–84) | 85 (78–90) | 76 (67–82) |
| Anti-CCP positive, % (95% CI) | 75 (66–80) | 82 (74–88) | 79 (72–85) |
| Initial TNFi, % of each agent (95% CI) | |||
| Adalimumab, n = 204 | 51 (44–58) | 29 (23–36) | 20 (15–26) |
| Etanercept, n = 290 | 43 (37–49) | 24 (19–30) | 33 (27–38) |
| Infliximab, n = 69 | 46 (34–59) | 19 (10–30) | 35 (24–47) |
TNFi tumor necrosis factor inhibitor, CI confidence interval, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide antibody